NasdaqGS:BCRXBiotechs
BioCryst Pharmaceuticals (BCRX) Profitability Surge Tests Bullish Growth Narratives
BioCryst Pharmaceuticals (BCRX) closed out FY 2025 with Q4 revenue of US$406.6 million and basic EPS of US$1.17, alongside net income of US$245.8 million. Trailing twelve month revenue stood at US$874.8 million and basic EPS at US$1.26. The company’s quarterly revenue moved from US$131.5 million in Q4 2024 to US$145.5 million in Q1 2025, US$163.4 million in Q2, US$159.4 million in Q3, and US$406.6 million in Q4. EPS shifted from a loss of US$0.13 in Q4 2024 to positive readings across each...